Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab

J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e135-e137. doi: 10.1111/jdv.18673. Epub 2022 Nov 5.

Authors

Maria E Baffa¹, Roberto Maglie¹, Francesca Montefusco¹, Carlo Pipitò¹, Stefano Senatore¹, Emiliano Antiga¹

Affiliation

¹ Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.

PMID: 36268775
DOI: 10.1111/jdv.18673

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19*
Humans
Pemphigoid, Bullous* / drug therapy
Rituximab / therapeutic use
Vaccination

Substances

COVID-19 Vaccines
dupilumab
Rituximab